Molecular pathology of primary and metastatic ductal pancreatic lesions: Analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions

Cancer

Volumn 79, Issue 4, 1997, Pages 700-716

  Ruggeri, Bruce A ^a   Huang, Lingyi ^a   Berger, David ^a   Chang, Hong ^a   Klein Szanto, Andres J P ^b   Goodrow, Tamra ^b   Wood, Moira ^a   Obara, T ^c   Heath, C W ^d   Lynch, H ^e  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d AMERICAN CANCER SOCIETY   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA sequencing; immunohistochemistry; mdm 2; p21 WAF 1; p53; pancreatic adenocarcinoma; single strand conformation polymorphism analysis

Indexed keywords

GENE PRODUCT; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; FETUS; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL, BREAST; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE ANALYSIS, DNA; SMOKING; TUMOR CELLS, CULTURED;

EID: 0031047115     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970215)79:4<700::AID-CNCR7>3.0.CO;2-H     Document Type: Article

References (80)

1. Warshaw AL, Femandez-Del Castillo C. Pancreatic carci-noma. N Eng J Med 1992; 326:455-65.
2. Murr MM, Sarr MG, Oishi AJ, van Heerden JA. Pancreatic cancer. CA Cancer J Clin 1994; 44:304-18.
3. Hahn SA, Kern SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995; 75:857-69.
4. Lumadue JA, Griffin CA, Osman M, Hruban RH. Familial pancreatic cancer and the genetics of pancreatic cancer. Surg Clin North Am 1995; 75:845-55.
5. Silverman DT, Dunn JA, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer lnst 1994; 86:1510-15.
6. Gold EB. Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am 1995; 75:819-43.
7. Hruban RH, van Mansfeld ADM, Offerhaus GJA, van Weering DHJ, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. Am J Pathol 1993; 143:545-54.
8. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102:230-36.
9. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, et al. Frequent c-Ki-ras Oncogene Activation in Mucous Cell Hyperplasias of Pancreas Suffering from Chronic Inflammation. Cancer Res 1993; 53:953-6.
10. Cerny WL, Mangold KA, Sarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the syryian golden hamster. Cancer Res 1992; 52:4507-13.
11. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Buchler MW. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996; 74:35-42.
12. Tsutsumi M, Yasui W, Naito A, Ohashi K, Kobayashi E, Noguchi O, et al. Expression of cripto in Human Pancreatic Tumors. Jpn J Cancer Res 1994; 85:118-21.
13. Yokoyama M, Funatomi H, Korbrin MS, Ebert M, Friess H, Buchler MW, et al. Betacellulin, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer. Int J Oncol 1995; 7:825-9.
14. Lemoine NR, Hughes CM, Barton CM, Poulson R, Jeffery RE, Kloppel G, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166:7-12.
15. Smith J, Derynck R, Korc M. Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U.S.A. 1987; 84:7567-70.
16. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993; 53:5289-96.
17. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. Aberrant expression of Type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993; 53:4741-4.
18. Leung HY, Hughes CM, Kloppel G, Williamson RCN, Lemoine NR. Localisation of expression of fibroblast growth factors and their receptors in pancreatic adenocarcinoma by in situ hybridisation. Int J Oncol 1994; 4:1219-23.
19. Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 1994; 59:667-75.
20. Siddiqi I, Funatomi H, Kobrin MS, Friess H, Buchler MW, Korc M. Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995; 215:309-15.
21. Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995; 62:529-35.
22. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994; 54:5775-8.
23. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55:1129-38.
24. McKie AB, Filipe MI, Lemoine NR. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer, Int J Cancer 1993; 55:598-603.
25. Yashima K, Nakamori S, Murakami Y, Yamaguchi A, Hayashi K, Ishikawa O, et al. Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. Int J Cancer 1994; 59:43-7.
26. Barton CM, McKie AB, Hogg A, Bia B, Elia G, Phillips SMA, et al. Abnormalites of the Rb1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol Carcinog 1995; 13:61-9.
27. Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJP, Lynch HT, et al. Molecular and immunochemical analyses of Rb1 and Cyclin D1 human ductal pancreatic carcinomas and cell lines. Mol Carcinog 1996; 15:85-95.
28. Hohne MW, Haiatsch ME, Kahl GA, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992; 52:2616-9.
29. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutle M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27-33.
30. Huang L, Goodrow TL, Zhang S-Y, Klein-Szanto AJP, Chang H, Ruggeri BA. Deletion and mutation analysis of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinoma. Cancer Res 1996; 56:1137-41.
31. Barton CM, Staddon SL, Hughes CM, Hall PA, Sullivan CO, Kloppel G, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64:1076-82.
32. Ruggeri B, Zhang S-Y, Caamano J, Di Rado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and RB-1 tumor suppressor genes. Oncogene 1992; 7:1503-11.
33. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Laver G, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8:289-98.
34. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142:1534-43.
35. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54:1556-60.
36. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33.
37. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995; 86:174-81.
38. Yokoyama M, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14:2477-84.
39. Casey G, Yamanaka Y, Friess H, Buchler M, Korc M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69:151-60.
40. Rall CJN, Yan Y-X, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, et al. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 1996; 12:10-17.
41. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994; 145:1291-5.
42. Berrozpe G, Schaeffer J, Pienado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994; 58:185-91.
43. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, et al. lmmunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118:150-4.
44. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, et al. Overexpression of p53 protein adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101:684-8.
45. Lee EY, Cibull ML, O'Daniel-Pierce E, Strodel WE, Jennings CD. Expression of p53 protein in pancreatic adenocarcinoma. Int J Pancreatol 1995; 17:237-42.
46. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
47. Lee JM, Abrahamson JLA, Bernstein A. DNA damange, oncogenesis, and the p53 tumor suppressor gene. Mutat Res 1994; 307:573-81.
48. Kouzarides T. Functions of pRb and p53: what's the connection? Trends Cell Biol 1995; 5:448-50.
49. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner, D, Weger AR, et al. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 1996; 74:279-89.
50. Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, Heitz PV, et al. Pancreatic acinar cell carcinoma: an analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993; 143:685-98.
51. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 1992; 52:5061-4.
52. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147:884-8.
53. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler K, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
54. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13:301-6.
55. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
56. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54:1169-74.
57. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21-CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82:675-84.
58. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/Cip-1) during differentiation. Oncogene 1994; 9:3389-96.
59. Cip1 in muscle and other terminally differentiating cells. Science 1995; 267:1024-7.
60. Reznek RH, Stephens DH. The staging of pancreatic adenocarcinoma. Clin Radiol 1993; 47:373-81.
61. Auerbach O, Garfinkel L. Histologic changes in pancreas in relation to smoking and coffee-drinking habits. Dig Dis Sci 1986; 31:1014-20.
62. Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Totsch M, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol 1995; 48:M12-M16.
63. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53:2231-4.
64. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85:1657-69.
65. Goelz SE, Hamilton SR, Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 1985; 130:118-26.
66. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic ostersarcoma. Cancer Res 1993; 53:16-8.
67. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51:4090-6.
68. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84:3781-4.
69. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986; 6:1379-85.
70. Hall PA, Lemoine NR. Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J Pathol 1992; 166:97-103.
71. Reddy JK. Progress in pancreatic cancer: implications of phenotypic and molecular plasticity. Lab Invest 1995; 72:383-6.
72. Wynford-Thomas D. p53 in tumor pathology: can we trust immunohistochemistry? J Pathol 1992; 166:329-30.
73. Ruggeri BA, Klein-Szanto AJP, Huang L-Y, Lang D. p53 and RB-1 tumor-suppressor gene expression and alterations in human pancreatic cancer. Int J Pancreatol 1994; 16:193-6.
74. Vahakangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, Harris CC. Mutations of p53 and K-ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339:576-80.
75. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994; 54:2761-4.
76. Brentnall TA, Chen R, Lee JG, Kimmey MB, Broner MP, Haggitt RC, et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995; 55:4264-7.
77. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-6.
78. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 1995; 378:206-8.
79. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21-WAF1. Cancer Res 1995; 55:4536-9.
80. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.